Enwei Pharmaceutical Co. Ltd. A
Enwei Pharmaceutical Co., Ltd. engages in the development and sale of Chinese medicines in China. The company offers drugs in the areas of gynecology, pediatrics, and respiratory system fields. The company was founded in 2005 and is based in Chengdu, China.
Enwei Pharmaceutical Co. Ltd. A (301331) - Total Liabilities
Latest total liabilities as of June 2025: CN¥433.11 Million CNY
Based on the latest financial reports, Enwei Pharmaceutical Co. Ltd. A (301331) has total liabilities worth CN¥433.11 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enwei Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Enwei Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enwei Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Enwei Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NRJ Group
PA:NRG
|
France | €183.87 Million |
|
FutureFuel Corp
NYSE:FF
|
USA | $34.37 Million |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
USA | $6.61 Billion |
|
Globus Spirits Limited
NSE:GLOBUSSPR
|
India | ₹11.42 Billion |
|
Oncolytics Biotech Inc
NASDAQ:ONCY
|
USA | $14.94 Million |
|
Bonduelle SCA
F:BDU
|
Germany | €1.38 Billion |
|
Smartoptics Group AS
OL:SMOP
|
Norway | Nkr23.55 Million |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:200011
|
China | HK$13.40 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Enwei Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enwei Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enwei Pharmaceutical Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Enwei Pharmaceutical Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥446.86 Million | +90.71% |
| 2023-12-31 | CN¥234.31 Million | -7.41% |
| 2022-12-31 | CN¥253.08 Million | +11.57% |
| 2021-12-31 | CN¥226.84 Million | -13.53% |
| 2020-12-31 | CN¥262.34 Million | -0.50% |
| 2019-12-31 | CN¥263.66 Million | -- |